Stocks Health care TPST
NASDAQ · Health careTempest Therapeutics, Inc. (TPST)
It posted a net loss of $40.5M. In fiscal 2025 capital spending exceeded operating cash flow by $26.8M. At June 30, 2026 it held $779K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Tempest Therapeutics, Inc.
- Net worth
- Tempest Therapeutics, Inc. has a market value (market cap) of $6.9M at the latest share price, and shareholders' equity of -$1.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $26.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tempest Therapeutics, Inc.'s next report was expected around October 20, 2026 and is not on file with the SEC yet.
What Tempest Therapeutics, Inc. does
Tempest Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TPST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26.3M | -$6.33 | -$26.8M |
| 2024 | n/a | -$41.8M | -$19.50 | -$33.5M |
| 2023 | n/a | -$29.5M | -$24.83 | -$27.5M |
| 2022 | n/a | -$35.7M | -$40.17 | -$31.6M |
| 2021 | n/a | -$28.3M | -$97.11 | -$26.1M |
| 2020 | n/a | -$19.2M | -$533.39 | -$19.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Tempest Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026Executive or director change8-KTempest Therapeutics entered into a research services agreement with Factor Bioscience, appointed a new director to regain Nasdaq compliance, and appointed a new Chief Financial Officer.
- September 25, 2026
- September 17, 2026
- September 16, 2026Additional proxy material DEFA14A
- September 16, 2026
- September 15, 2026
- August 24, 2026
- August 21, 2026IPO registration S-1
- August 18, 2026Additional proxy material DEFA14A
- August 18, 2026
Insider trades
What the people running Tempest Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 24, 2026 | Angel MatthewCEO and President, Director, 10% owner | Boughtindirect | 231,482 | $500K |
| March 24, 2026 | Angel MatthewCEO and President, Director, 10% owner | Boughtindirect | 231,482 | $500K |
Who owns TPST
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Matthew Angel13D, may seek influence | 37.4% | March 25, 2026 |
| Sabby Management, LLC13G, passive with 2 related filers | 9.9% | January 21, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 231,482 shares in total, about $99.5K at the last price.
| Holder | Shares |
|---|---|
| Angel MatthewCEO and President, Director, 10% owner | 231,482231,482 held indirectly |
Questions about TPST
What does Tempest Therapeutics, Inc. do?
Tempest Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TPST. Its shares trade on NASDAQ under the ticker TPST.
What is Tempest Therapeutics, Inc.'s net worth?
Tempest Therapeutics, Inc. has a market value (market cap) of $6.9M at the latest share price, and shareholders' equity of -$1.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tempest Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $40.5M.
When did Tempest Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 2, 2026.
When is Tempest Therapeutics, Inc.'s next earnings report?
Tempest Therapeutics, Inc.'s next report was expected around October 20, 2026 and is not on file with the SEC yet.
Similar companies
Compare TPST with
Follow TPST
Get an email when Tempest Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tempest Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.